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THE host response to neoplasia may be quite variable depending on the para-
meter observed, the strain or species of animal studied, nutritional state of the
animal, and other factors. Of the various parameters considered, the one which
stands out as the most nearly universal host response to early neoplasia is the
depression in hepatic catalase activity. This subject has been reviewed by
Greenstein (1954). The enzyme delta-aminolevulinic acid dehydrase may show
a response similar to that ofcatalase (Tschudy and Collins, 1957). The underlying
mechanism of this catalase response has been studied extensively and has led to
a consideration of the following factors: (1) That the tumor elaborates a " toxo-
hormone " which depresses catalase activity (Nakahara and Fukuoka, 1948;
Fukuoka and Nakahara, 1951; Greenfield and Meister, 1951; and Ceriotti and
Spandrio, 1955); (2) that the depression may be related to the presence ofexcess
sulphydryl groups or ascorbic acid which could give rise to an inactive catalase-
H202 complex (Alexander, 1957); and (3) that the effect of a neoplastic growth.
maybesimilarto thatproduced byadministration of3-amino-1,2,4-triazole (Heim,
Appleman and Pyfrom, 1955; Heim, Appleman and Pyfrom, 1956; Sugimura,
1956; and Feinstein, 1958). This question is still unresolved.
Since the depressed hepatic catalase activity in tumor-bearing animals has
been established beyond doubt, it seemed worth while to investigate an enzyme
system whose function might be related in some way to the level of catalase
activity. With this in mind we undertook the study of myeloperoxidase (MPO)
in tumor-bearing mice. Myeloperoxidase, formerly called verdoperoxidase and
studied in detail by Agner (1941), is an iron-porphyrin- containing enzyme which
utilizes hydrogen peroxide as a substrate, the enzyme-substrate complex then
having the capacity to oxidize donor molecules such as aromatic amines, phenols,
and natural compounds such as epinephrine, ascorbic acid, etc. (Theorell, 1951).
Since this enzyme has thus far been demonstrated only in cells of the myeloid
series, this study was carried out on bone marrow tissue.
MATERIALS AND METHODS
In order to develop quantitative data on a tissue such as mouse bone marrow,
we adopted the procedure of homogenizing the whole, cleaned mouse femur in
a Virtis " 23 " homogenizer. The femur was scraped clean of all adherent tissue
so as not to vitiate subsequent protein determinations performed on the extracts.
Some control observations on bone marrow tissue taken from rat femur gave
figures of the same order of magnitude as that obtained on the whole homo-HAROLD G. LOEB AND RUTH DONIGER
genized femur, so it was assumed that components of the bony matrix did not
significantly alter the activity of myeloperoxidase (MPO).
As reported by Bancroft and Elliott (1934), and earlier workers, we found that
extraction of tissue with phosphate buffer at pH 7-0 removed approximately
50 per cent of the total MPO activity which could be detected. Following a
procedure suggested by Wattiaux and de Duve (1956), and explored also by
Adams and Burgess (1957), we tried tissue extractions with phosphate buffer
containing 041 per cent Triton X100 and obtained activity levels substantially
greater than that obtained without Triton, approaching 100 per cent of the
detectable enzyme activity. A word ofcaution should be mentioned at this point.
In some extracts subjected to freezing at - 700 C., and thawing, additional MPG
activity could be detected. It is presumed that some finely divided material was
present in the extract and that this underwent structural alteration liberating
the additional activity (see below). We have been unable to elicit this effect
consistently. Although our standard procedure now allows the low temperature
storage of tissue, but not the extract, and involves treatment of the homogenate
withn-butanolfollowedbyassayoftheextractwithinafewhours, itwasconsidered
desirable to record some of our observations on stored extracts, prepared with
and without n-butanol. These observations are discussed below.
Since phosphate buffer of low ionic strength is generally used in the assay
reaction mixture, and phosphates have been reported to weaken the peroxidase
reaction withguaiacol (Ostrovskaja, 1950), it seemed advisable to select a different
buffer, and one which would be less influenced by the composition ofthe sample.
For these reasons tris buffer at pH 7 0 was tested and found to give results com-
parable with phosphate buffer.
Increasing the ionic strength of the guaiacol reagent with sodium chloride
increased the measured activity. With a final sodium chloride concentration in
the reagent of 0-85 per cent, the activity was 34 per cent greater than at 0-45 per
cent. With 125 per cent NaCl concentration, the activity was only 10 per cent
greater than at 0*85 per cent.
Treatment of the homogenate with n-butanol for 5 minutes served to break
the emulsion which formed during homogenization, and also increased the activity
by 5-10 per cent. It was found, however, that when extracts were prepared with
n-butanol and stored at - 700 C. protein denaturation occurred more rapidly
than when n-butanol was not used. As noted below, extracts prepared with
n-butanol and stored at - 700 C. seemed to liberate more activity, if not stored
too long, and to suffer more rapid denaturation when storage was prolonged.
Reagents
Stock tris solution: 0-2 M tris-(hydroxymethyl)-aminomethane (Sigma
7-9). Tris buffer, 0.02 M: 100 ml. of 0.2 M tris and 94 ml. of 0-2 N HCI
made to 1 L, pH = 7-0-7-1. Stock H202, 1*0 M: made from 30 per cent H202
and standardized with permanganate. Working solution H202, 01 M: 1: 10
dilution of stock solution, prepared fresh each week. Tris-triton solution: 1: 1
mixture of 0*02 M tris buffer and 0-2 per cent Triton X100 (Rohm and Haas
Co.). Sodium chloride solution: 1-70 per cent NaCl. Guaiacol reagent: 0-22 g.
guaiacol, cryst. (Amend), made to 100 ml. with a 1: 1 mixture of 0-02 M tris
buffer and 1-70 per cent NaCl, prepared fresh each week.
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Procedure
The mouse is sacrificed with ether, the hind limbs are promptly disarticulated
and the femurs removed and stored at - 150 C. for at least 10 minutes. Thefrozen
femurs are then carefully trimmed and scraped free of all adherent tissue, trans-
ferred to small test tubes and stored at - 700 C. until taken for assay. In control
studies no significant differences in MPO activity were observed in femurs stored
up to 17 days. Longer storage periods were not tested. The frozen femur is cut
with scissors into the stainless steel Virtis homogenizing vessel which contains
0-5 ml. of tris-Triton, and is kept cold with ice cubes. Homogenization is carried
out at 13,000 r.p.m. for 2 minutes. While the shaft is revolving slowly, 25 ,ul. of
n-butanol (5 per cent) are added gradually. The emulsion is readily broken and
stirring is continued for 5 minutes. The cold homogenate is transferred to a cold
1 ml. microcentrifuge tube, the steel vessel is rinsed with 0 3 ml. and 0-2 ml. of
tris-Tritonsolution, and the rinsings are added to thehomogenateandmixed. The
tubes are then centrifuged in the cold (40 C.) for 3 minutes at 10,000 r.p.m. (5200
G.). The supernatant fluid is then decanted and kept in an ice-bath until assayed.
The assay is performed at three levels (25-100 ,ul.) essentially as described by
0*22 Colowick and Kaplan (1955), using k1 conditions. Since k1 = eAt we have ex-
0*22 pressed our activity units as "e" = ek, = i-t where e is the enzyme concentra-
tion in M/L and At is the time, in seconds, for an increase in optical density of
0 05, after addition of hydrogen peroxide. When the k1 dissociation constant is
accurately known (of the order of 107), " e " can readily be translated into
absolute units.
Protein determinations on the bone marrow extracts were performed with the
biuret procedure of Gornall, Bardawill and David (1949), using Armour's crystal-
line bovine albumin as a standard. Specific activity values are expressed as " e
per gram ofprotein.
Experimental tumors
Bone marrow MPO levels were measured against time after inoculation or
implantation with three different types of tumor, the Ehrlich ascites carcinoma,
C-1498 myelogenous leukaemia, and Sarcoma 180. Twenty-gram mice were
employedinall cases, using theC57 Bl miceforthe C-1498 implantsandSwissWeb-
ster mice for the other two tumors. The Ehrlich ascites carcinoma was inoculated,
intraperitoneally, as 0*1 ml. of a 7-day growth. This inoculum was assumed to
contain 107 cells. The C-1498 and S-180 tumors were implanted as tumor bits in
the right axillary region with the conventional trocar technique. Control mice for
the Ehrlich ascites experiments received intraperitoneal injections of normal
saline; controls in the C-1498 experiment were untreated; and controls in the
S-180 experiment were subjected to sham implants by trocar.
RESULTS
Ehrlich ascites carcinoma
In a preliminary experiment involving three control mice and three inoculated
with Ehrlich ascites carcinoma, one experimental animal and its control were
sacrificed and assayed for MPO on days 2, 6, and 8 after inoculation. Extracts
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of the left and right femurs of each animal were prepared without n-butanol and
assayed separately without storage. The MPO specific activity showed a linear
increase against time amounting to 7*7 per cent per day. The same experiment
was repeated using four control and six experimental mice (Expt. EMA-J). The
latter were sacrificed in groups of two on days, 1, 3, and 6 after inoculation and
each femur was assayed separately. These specific activity values were of the
same magnitude as in the preliminary experiment and are shown in Table I.
TABLE I.-Experiment EMA-I. Myeloperoxidaae ActivityofBone MarrowExtracts
from Mice uith Ehrlich Ascites Carcinoma
Spec. act. Protein
Group N (" e -/g.) (mg./ml.)
Control:
Day 0 4 97±7-1* . 1.39±0-20*
8 4 79±5 5 1*40±0*04
Experimental:
Day 1 . . 4 . 94±13-0 . 1-46±0-05
3 4 107±9-5 . 134±0-06
6 . 4 130±9.0 . 1-48±0-04
* Standard error.
Statistically significant differences in specific activity could not be demonstrated
between the controls and day 1 and day 3 animals, but the day 6 mice showed
an increase over the controls exceeding three standard deviations, or four times
the standard error. When the data are plotted, one finds again a linear increase
of MPO specific activity amounting to 7-7 per cent per day. Protein levels were
the same in control and experimental extracts.
The experiment was repeated with eight control and twelve experimental
mice (Expt. EMA-JI) and in this case the experimental animals were sacrificed
on the first 6 consecutive days after inoculation, two on each day. Controls were
sacrificed on days 0, 2, 4, and 6. In addition, the bone marrow extracts from the
right and left femur of each mouse were prepared with n-butanol, pooled, and
stored at - 700 C. for 2 weeks before assay. These results are shown in Table II.
Here one observes that both the control and experimental specific activity values
are substantially higher than those obtained in the previous experiment. Further-
more, the experimental levels are appreciably higher than the controls, + 5845
per cent, and this increase appears to have occurred abruptly. This was the
only experiment which yielded such high values, and the only one in which the
extracts prepared with n-butanol were stored before assay. As mentioned above,
these results indicate that storage of extracts at - 700 C. can liberate additional
activity. However, preliminary tests ofthis observation gave inconsistent results.
One gains the impression that liberation of activity and destruction of enzyme
under these conditions are occurring simultaneously and at different rates. A
comparison ofthis experiment with the preceding one suggests that there may be
two forms ofmyeloperoxidase, that one form is readily extractable under the con-
ditions described above, and that the other form becomes progressively more
extractable when a neoplastic process is present. The higher values for both
the control and experimental extracts of experiment EMA-II are probably due
to the presence ofn-butanol in the extract plus storage at - 700 C. These condi-
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TABLE II.-Experiment EMA-II. Myeloperoxidase Activity of Bone Marrow
Extractsfrom Mice with Ehrlich Ascites Carcinoma
Spec. act. Protein
(" e "1g.) (mg./mI.) Group N (ave.) (ave.)
Control:
Day0 . . 2 . 123 . 155
2 . . 2 . 188 . 1-71
4 . . 2 . 130 . 2-40
6 . . 2 . 166 . 1*61
Mean: 152 . 182
Experimental:
Dayl . . 2 . 263 . 1.51
2 . . 2 . 248 . 1*24
3 . . 2 221 . 1*67
4 . . 2 . 212 1*40
5 . 2 278 . 1-40
6 . . 2 . 226 . 1-48
Mean: 241 . 145
tions appear to bring about the abrupt release ofactivity which would otherwise
occurgradually as the tumor developed. If one assumes that the values fortotal
MPO specific activity in experiment EMA-I should be higher by 64 " e "/g.
(152-88), the day 6 value would become 194, indicating that as the neoplasia
progresses, the liberation of total MPO activity is being approached.
C-1498 myelogenow8 leukemia
In this experiment, four control and twelve experimental micewere employed.
The extracts in this instance were prepared without n-butanol treatment. These
resultsarepresentedinTableIII. Thecontrolvalues arehigherthanthoseobserved
TABLE III.-Myeloperoxidase Activity of Bone Marrow Extracts from Mice with
C-1498 Myelogenow Leukemia
Spec. act. Protein
(e /g.) (mg./ml.) Group N (ave.) (ave.)
Control:
Day1 . . 2 . 128 . 137
6 . . 2 . 136 . 1*57
Experimental:
Dayl . . 2 . 156 . 1 74
2 . . 2 . 165 . 1B50
3 . . 2 . 177 . 1*49
4 . . 2 . 160 . 1*49
5 . 2 . 165 . 1-39
6 . . 2 . 130 . 156
in experiment EMA-J; this difference may be characteristic ofthe C57 Bl mouse.
Greenstein (1954, p. 521) has noted that the C57 Bl mouse has a much lower
hepatic catalase level than all the other strains studied. The increased MPO
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activity is again observed in the tumor-bearing animals; but in this case the
level has dropped back to the control value on the sixth day. Again, no significant
change in the protein content ofthe extract was observed.
Sarcoma 180
Nineteen mice were studied in this experiment, the seven control micereceiving
sham implants by trocar. The extracts were prepared with n-butanol, kept in
an ice-bath, and all were assayed within 3 hours after preparation. Extracts of
the right and left femur from each mouse were pooled after preparation. In Table
IV one will note that the specific activity of the day 0 control mice is higher
than the day 2 and day 4 values. This is probably a stress response since the
TABLE IV.-Myeloperoxidase Activity of Bone Marrow Extracts from
Mice with Sarcoma 180
Spec. act. Protein
(" e "/g.) (mg./ml.)
Group N (ave.) (ave.)
Control:
Day0 . 2 . 123 . 166
2 . 2 . 92 . 1-84
4 . 3 100 . 1-71
Experimental:
Day1 . . 2 . 124 1 80
2 . 2 117 . 1*68
3 . 2 116 . 1*73
4 . 2 . 123 . 1-67
5 . 2 . 141 . 1*90
6 . 2 . 149 1-78
animals were sacrificed only 4 hours after the sham implant. The higher value for
the day 1 experimental mice is also very likely a reflection of the imposed stress.
If the average of the day 2 and day 4 controls, 96, is taken as the normal value,
we find in the experimental group a 21 per cent increase inMPG activity on day 3,
28 per cent on day 4, 47 per cent on day 7, and 55 per cent on day 9. This response
is essentially linear, approximating 5x8 per cent per day. The protein content of
the extracts remains unchanged.
DISCUSSION
In the three different types of experimental tumor investigated, an increase
in the level of bone marrow myeloperoxidase activity was observed, associated
with early neoplasia. The normal C57 Bl mouse, which shows a lower hepatic
catalase level than other strains, shows a higher bone marrow MPO level and,
in contrast to the Swiss Webster mouse, showed a rise and then a fall in MPO
activity in the presence of a growing tumor. With the Ehrlich ascites carcinoma
and Sarcoma 180 we have found a progressive increase in bone marrow MPO
activity. The results in experiment EMA-JI suggest that the presence of tumor
cells is not only associated with a higherlevel ofMPO activity in the bone marrow,
but may also bring about a progressive liberation of the enzyme-or its active
centers. This observedincreaseinMPOdoes notsupportthesuggestionofFukuoka
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and Nakahara (1951) that the presence of a tumor may result in the binding
of iron with a consequent depression of all iron-porphyrin-containing enzymes.
Sinceverylittleisknownaboutthephysiologicalfunctionofanimalperoxidases
one can do little more than speculate on the significance ofthese findings. Neufeld
et al. (1955) observed an increase in rat uterine peroxidase in response to estrogen
administration and Lucas et al. (1955) were able to detect peroxidase activity in
the Walker 256 rat carcinoma. They suggested that the enzyme might be involved
in terminal respiration. The adaptive response of liver tryptophan peroxidase
to elevated tryptophan levels (Knox and Mebler, 1950, 1951; Price and Dietrich,
1957) and of cytochrome-c peroxidase of Pseudomonas fluorescen8 to low oxygen
tensions (Lenhoff and Kaplan, 1956) suggests that the increase in MPO activity
in the presence of tumor may also be a type of adaptive response. Much more
work is required to elucidate the true significance of these findings.
SUMMARY
1. Evidence was presented showing a progressive increase in the level ofmyelo-
peroxidase activity in bone marrow extracts of mice bearing the Ehrlich ascites
carcinoma, C-1498 myelogenous leukemia, and Sarcoma 180. The C57 Bl mouse
which normally has a lower hepatic catalase level than the Swiss Webster mouse
was found to have a higher bone marrow MPO level. In this strain the bone
marrow MPO level of the tumor-bearing mouse dropped back to normal on day
6 after implantation.
2. The results of an experiment with the Ehrlich ascites carcinoma suggested
the possibility of two forms of myeloperoxidase with one form being increased
in the presence of neoplasia, and progressively liberated as the neoplastic growth
develops.
We are indebted to Dr. Byron E. Hall for providing the assistance which
made it possible for this work to go forward.
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